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selected using the PharMetrics Patient-Centric Database. All
patients were assumed to be on original therapy for the ﬁrst
month, with discontinuation rates derived from the subsequent
11-month period. Medical costs were estimated based on payer
reimbursements for all services rendered to TOL and OXY
patients matched for demographic and pretreatment clinical
characteristics. Subsequent costs for those who discontinued
therapy were based on patients receiving medical management
without drug therapy (n = 29,992). Costs for drugs were pro-
vided by AnalySource (October 2004). RESULTS: After the 
11-month follow-up period, 21% of TOL and 15% of OXY
patients remained on original therapy. Mean total health care
costs per patient were $8876/y for those originally on TOL and
$9080/y for those started on OXY. Sensitivity analyses indicated
that results were robust to changes in drug cost and probability
of discontinuation. When persistence was held equal, cost dif-
ferences continued to favor TOL: 21% = $272/year and 15% =
$233/year. Furthermore, for the model to result in equivalent
annual health care costs, TOL cost must increase by $1.50/day
or OXY cost must decrease by $1.62/day. CONCLUSIONS: At
the end of one year, OAB patients were more likely to remain on
original treatment taking TOL versus OXY. This resulted in a
total health care cost savings of $204 per patient.
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OBJECTIVE: We compared the direct health care costs for
patients receiving different prescription pharmacologic agents
for overactive bladder (OAB) symptoms in a managed care
setting. METHODS: We used administrative medical and phar-
macy claims data from >30 managed care plans. Patients newly
diagnosed with OAB who initiated treatment with tolterodine
extended release (TOL ER), oxybutynin extended release (OXY
ER), or oxybutynin immediate release (OXY IR) were followed
for 12 months from the date of initial diagnosis. Patients were
required to be continuously eligible for pharmacy and medical
beneﬁts during the study period. Total mean medical costs 
were assessed for the 12-month follow-up period and were com-
pared across the treatment groups after statistical adjustment for
age, sex, and days to treatment initiation. Medical costs were
calculated from inpatient admissions, emergency room visits,
outpatient physician visits, other prescription drugs, and diag-
nostic/laboratory services. RESULTS: A total of 6110 patients
initiated treatment with TOL ER (mean age 55y, 77% women),
3325 with OXY ER (mean age 55y, 73% women), and 893 with
OXY IR (mean age 57y, 61% women). Patients who received
OXY ER ($9063) and OXY IR ($10,523) had signiﬁcantly
higher adjusted annual mean medical costs than did patients who
received TOL ER ($8073, p = 0.0175 and p = 0.0001, respec-
tively). CONCLUSIONS: Diagnosing and managing patients
with OAB is challenging, especially as it relates to pharmacologic
treatment. Observed lower medical costs of TOL ER patients in
this study may have broad implications. Results from this study
warrant further analysis that fully incorporates adjustments for
the factors associated with treatment selection as well as disease-
speciﬁc drivers of health care costs.
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OBJECTIVE: To assess the economic impact of everolimus 1.5
mg with reduced-dose cyclosporine (CsA) vs. mycophenolate
moteﬁl (MMF2g) with full dose CsA in de novo renal transplant
recipients. METHODS: A previous trial (B201) which prospec-
tively collected resource utilization during one-year showed
similar economic outcomes for everolimus vs. MMF2g with 
full-dose CsA. Direct medical costs (excluding everolimus, 
CsA and MMF) were mostly dependent on key clinical events:
hemodialysis, length of stay (LOS) due to adverse events (AE) 
or infection (INF), biopsy proven acute rejection (BPAR) and
days on cytomegalovirus (CMV) therapy. A subsequent trial of
everolimus with reduced-dose CsA demonstrated similar efﬁcacy
(A2306). A multivariate model was ﬁtted on the B201 data to
predict direct medical costs. Coefﬁcients were then applied to the
A2306 data to predict the economic outcomes of everolimus
with reduced-dose CsA. As no signiﬁcant country-speciﬁc cost
effect on LOS was found, individual country cost vectors were
applied (Germany, France and Spain). RESULTS: For Germany,
incremental costs were 250€ per hemodialysis session (p <
0.001), 261€ per day of hospitalization due to AE (p < 0.001),
343€ per day of hospitalization due to INF (p < 0.001) and
4473€ per BPAR (p < 0.001). After adjusting for recipient age,
living donors, and CMV therapy between B201 and A2306,
everolimus with reduced-dose CsA decreased 1-year costs by
3260€ vs. MMF with full-dose CsA. Taking into account cost 
of CsA, MMF and everolimus (assuming parity pricing of
everolimus 1.5mg and MMF 2g), everolimus with reduced-dose
CsA decreased total 1-year costs in Germany by 3960€. In Spain
and France, the ﬁnal cost-savings would be 1516€ and 3217€,
respectively. CONCLUSION: In de novo kidney transplant
recipients over a 1-year follow-up period, everolimus 1.5mg 
with reduced-dose CsA is a cost-saving strategy compared to
MMF-based regimen. Further analyses in other health care set-
tings are needed to fully document the cost-saving of everolimus
1.5mg.
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OBJECTIVES: To develop a decision analytic model comparing
the cost-effectiveness of various preparations of oxybutynin 
and tolterodine in the treatment of overactive bladder (OAB).
METHODS: The model included immediate-release oxybutynin
(OxyIR), extended-release oxybutynin (OxyER), transdermal
oxybutynin (OxyTD), immediate-release tolterodine (TolIR),
and extended-release tolterodine (TolER). Treatment success was
deﬁned as complete continence (no incontinence episodes). The
model was constructed from the payer’s perspective, assuming
incontinence pads were a covered beneﬁt. The timeframe for the
model was three months. Costs included were medications,
incontinence pads, and treatment of OAB-induced morbidities
(i.e., urinary tract infections, fractures, depression, and skin
infections). The selection of clinical outcomes data was based on
the following priority: 1) FDA approval label; 2) randomized
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controlled trials; and 3) previous pharmacoeconomic OAB
studies. Due to lack of variance for success rate in published
reports, sensitivity analyses used +/- 50%. RESULTS: Success
rates for the treatments were 35.6%(OxyIR), 23.0%(OxyER),
39.0%(OxyTD), 24.6%(TolIR), and 16.8%(TolER). Cost per
complete continence was lowest for OxyIR ($5777), followed by
OxyTD ($6189), TolIR ($8658), OxyER ($9121), and TolER
($11,850). OxyER, TolIR, and TolER were dominated by OxyIR
and OxyTD. Comparing OxyIR, use of OxyTD was an addi-
tional $9916 per person with complete continence. Sensitivity
analyses found that success rate was the key parameter driving
the analysis. When the success rate of OxyIR varied from 17.8%
to 53.4%, the ICER of OxyTD changed from $1462 to being
dominated. When the success rate of OxyTD varied from 19.5%
to 58.5%, the ICER of OxyTD changed from being dominated
to $1151. Sensitivity analyses of other model parameters were
found to not change the rank orders of treatments. CONCLU-
SION: The results of this study suggested OxyIR is the most 
cost-effective treatment for overactive bladder among various
preparations of oxybutynin and tolterodine. The second cost-
effective agent is OxyTD.
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OBJECTIVE: To evaluate the economic value of a pharmaceu-
tical product, Kremezin, in treating patients with chronic renal
failure (CRF) by estimating the amount of cost savings due to its
effect of delaying the onset of receiving dialysis treatments.
METHODS: The types of costs included were direct medical and
non-medical costs, and productivity loss costs. The information
about the effect of Kremezin was obtained from the results of
randomized controlled clinical trials. Cost information was
derived from administrative data for 20 hemodialysis and 20
peritoneal patients from one tertiary care hospital, and 20
hemodialysis patients from one free-standing dialysis center. Per-
capita cost savings resulting from Kremezin therapy were sepa-
rately estimated for the cases delaying the onset of hemodialysis
and the cases for peritoneal dialysis. By computing the weighted
average for the cases of hemodialysis and peritoneal dialsyis, the
expected per-capita cost savings of a patient with CRF was
obtained. Using the discount rate of 5%, future cost savings were
converted to the present value. Budget impact analysis was 
performed to estimate the expected national cost savings if 
Kremezin is administered to 25%, 50%, and 75% of the total
incident dialysis patients in 2004. RESULTS: Depending on the
effect of Kremezin in delaying the onset of dialysis treatments by
one, two, or four years, a patient with CRF could save costs by
1.8¢ 5.5, 1.6¢ 5.1 and 3.4¢ 10.6 million Korean Won (KW),
respectively from the perspectives of insurer, patient, and society.
Also, the national ﬁnancial impact of adopting Kremezin for
25%, 50%, and 75% of the total incident dialysis patients was
estimated as cost savings of about 61,511¢ 579,162 million KW
per year in Korea. CONCLUSION: The estimated amount of
cost savings resulting from treating CRF patients with Kremezin
conﬁrms that its effect of delaying the onset of dialysis treatments
has a considerable economic value.
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OBJECTIVE: To describe treatment utilization and associated
costs for women diagnosed with stress urinary incontinence in a
Medicaid population. METHODS: We utilized a pooled data-
base consisting of health care claims for women enrolled in 
Medicaid in one of four states. After identifying women with a
coded diagnosis consistent with stress urinary incontinence
(SUI), treatment utilization and costs were determined for the 12
months after the urinary incontinence diagnosis. RESULTS: Of
the 13,672 women with a diagnosis of SUI, average urinary
incontinence-related costs were approximately $800 in the 12-
month study period, accounting for less than 0.1% of total Med-
icaid spending. Approximately one-third of the SUI patients
received an anticholinergic medication in the study period,
though these medications are not indicated for SUI treatment. A
total of 13% of women underwent a surgery for SUI in the study
period, with sling procedures performed most commonly. Mean
UI-speciﬁc costs in the study period for the surgical and non-
surgical SUI patients were $3258 and $424 (p < 0.001) respec-
tively. CONCLUSIONS: While overall population estimates of
the prevalence of any stress urinary incontinence symptoms often
are high, diagnosis and treatment utilization in the Medicaid
population is low, and overall costs of SUI treatment in Medic-
aid currently are minimal. Further efforts to understand the
appropriate detection, diagnosis, and treatment of women with
SUI are needed.
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OBJECTIVES: This study assessed per patient direct medical
costs and indirect work loss of diagnosed interstitial cystitis
(“IC”) patients from an employer’s perspective. Treatment
pattern of IC was also assessed. METHODS: Patients under age
65 with at least one IC diagnosis (n = 749) were drawn from a
de-identiﬁed, administrative database of approximately two-
million beneﬁciaries that includes medical, drug, and disability
claims for 1999–2002. A 2 :1 matched non-IC control sample
was randomly selected based on matching demographic charac-
teristics (i.e. age, gender, region of residence). Annual costs and
comorbidities were compared between IC and the non-IC
samples descriptively. A multivariate two-part regression model
was applied to estimate IC excess medical costs and indirect
work loss costs while adjusting for observed patient demo-
graphics and comorbidities. All costs were adjusted to 2002 USD
using Consumer Price Index (“CPI”). Intent-to-treat approach
was adopted to proﬁle treatment patterns of IC. RESULTS: An
average IC patient had 130% higher direct medical costs ($3756)
and 80% higher indirect costs ($725) than a non-IC patient.
Compared with non-IC patients, IC patients had higher diag-
nostic prevalence of prostatitis (Relative Risk (“RR”) = 40.0, P
< 0.05), endometriosis (RR = 7.4, P < 0.05), vulvodynia (RR =
6.9, P < 0.05), chronic pelvic pain (RR = 5.8, P < 0.05), and
urinary tract infections (RR = 5.1, P < 0.05). IC patients were
also more likely to suffer from depression (RR = 2.8, P < 0.05)
